LENZ THERAPEUTICS, INC. Revenue
LENZ THERAPEUTICS, INC. (LENZ) reported Revenue of $5.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $5.49M, a 9.72% increase year-over-year.
- LENZ THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $1.90M.
- LENZ THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $5.00M.
- LENZ THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $0.00.
- LENZ THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $19.09M.
- LENZ THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|
| 2026-06-30 | $5.49M 10-Q · filed 2026-08-11 | $7.39M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $1.90M 10-Q · filed 2026-05-11 | ||
| 2025-12-31 | $19.09M 10-K · filed 2026-03-24 | ||
| 2025-06-30 | $5.00M 10-Q · filed 2026-08-11 | $5.00M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |